

# Next Edge Biotech and Life Sciences Opportunities Fund

## Quarterly Summary of Investment Portfolio as at September 30, 2023



The summary of investment portfolio may have changed since September 30, 2023 due to ongoing portfolio transactions of the Fund.

Portfolio by Asset Mix	% of Net Asset Value	
	Long	Short
United States Equity	52.7	-
Canadian Equity	18.7	-
Foreign Equity	12.8	-
Equity Options	5.5	(0.2)
Canadian Bond	3.0	-
United States Bond	1.6	-
Cash and Cash Equivalents	6.5	-
	100.8	(0.2)
Other Net Assets (Liabilities)		(0.6)
	100.8	(0.8)

Portfolio by Sector	% of Net Asset Value	
	Long	Short
Pharmaceuticals, Biotechnology & Life Sciences	68.7	-
Health Care Equipment & Services	15.5	-
Equity Options	5.5	(0.2)
Canadian Bond	3.0	-
United States Bond	1.6	-
Cash and Cash Equivalents	6.5	-
	100.8	(0.2)
Other Net Assets (Liabilities)		(0.6)
	100.8	(0.8)

Portfolio by Geography	% of Net Asset Value	
	Long	Short
United States	59.8	(0.2)
Canada	21.7	-
International	12.8	-
Cash and Cash Equivalents	6.5	-
	100.8	(0.2)
Other Net Assets (Liabilities)	-	(0.6)
	100.8	(0.8)

Next Edge Biotech and Life Sciences Opportunities Fund  
 Quarterly Summary of Investment Portfolio as at September 30, 2023



<b>Top 25 Long Positions</b>	<b>% of Net Asset Value</b>
Cash and cash equivalent	6.5
CRISPR Therapeutics AG	4.4
Opsens Inc.	3.9
Protalix BioTherapeutics Inc.	3.7
Microbix Biosystems Inc.	3.6
Schrodinger Inc.	3.3
10X Genomics Inc.	3.3
Nektar Therapeutics	3.1
Imagin Medical Inc., Private Bond, September 03, 2023	3.0
Verona Pharma PLC, ADR	2.7
ClearPoint Neuro Inc.	2.6
Phathom Pharmaceuticals Inc.	2.4
Delcath Systems Inc.	2.3
Blueprint Medicines Corp.	2.3
Avadel Pharmaceuticals PLC, ADR	2.1
Pacific Biosciences of California Inc.	2.1
Madrigal Pharmaceuticals Inc.	2.1
Synaptogenix Inc.	2.0
Fennec Pharmaceuticals Inc.	2.0
Cognetivity Neurosciences Ltd.	2.0
Galapagos NV, ADR	1.9
Eledon Pharmaceuticals Inc.	1.8
Bluebird Bio Inc.	1.8
SPDR S&P 500 ETF TRUST@410 PUT OPT 20 OCT 23	1.7
Clene Inc.	1.7

<b>Top 1 Short Positions<sup>1</sup></b>	<b>% of Net Asset Value</b>
SPDR S&P 500 ETF TRUST@390 PUT OPT 20 OCT 23	(0.2)

**Net Asset Value of Next Edge Biotech and Life Sciences Opportunities Fund as at September 30, 2023** \$8,434,417

1. There are no other short positions as at September 30, 2023